Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved..
BACKGROUND: Effective, safe, and affordable antivirals are needed for coronavirus disease 2019 (COVID-19). Several lines of research suggest that tenofovir may be effective against COVID-19, but no large-scale human studies with appropriate adjustment for comorbidities have been conducted.
METHODS: We studied HIV-positive individuals on antiretroviral therapy (ART) in 2020 at 69 HIV clinics in Spain. We collected data on sociodemographics, ART, CD4+ cell count, HIV-RNA viral-load, comorbidities and the following outcomes: laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, COVID-19 hospitalization, intensive care unit (ICU) admission and death. We compared the 48-week risks for individuals receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamide (TAF)/FTC, abacavir (ABC)/lamivudine (3TC), and other regimes. All estimates were adjusted for clinical and sociodemographic characteristics via inverse probability weighting.
RESULTS: Of 51 558 eligible individuals, 39.6% were on TAF/FTC, 11.9% on TDF/FTC, 26.6% on ABC/3TC, 21.8% on other regimes. There were 2402 documented SARS-CoV-2 infections (425 hospitalizations, 45 ICU admissions, 37 deaths). Compared with TAF/FTC, the estimated risk ratios (RR) (95% confidence interval) of hospitalization were 0.66 (0.43, 0.91) for TDF/FTC and 1.29 (1.02, 1.58) for ABC/3TC, the RRs of ICU admission were 0.28 (0.11, 0.90) for TDF/FTC and 1.39 (0.70, 2.80) for ABC/3TC, and the RRs of death were 0.37 (0.23, 1.90) for TDF/FTC and 2.02 (0.88-6.12) for ABC/3TC. The corresponding RRs of hospitalization for TDF/FTC were 0.49 (0.24, 0.81) in individuals ≥50 years and 1.15 (0.59, 1.93) in younger individuals.
DISCUSSION: Compared with other antiretrovirals, TDF/FTC lowers COVID-19 severity among HIV-positive individuals with virological control. This protective effect may be restricted to individuals aged 50 years and older.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
---|---|
Enthalten in: |
AIDS (London, England) - 36(2022), 15 vom: 01. Dez., Seite 2171-2179 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Del Amo, Julia [VerfasserIn] |
---|
Links: |
---|
Themen: |
2T8Q726O95 |
---|
Anmerkungen: |
Date Completed 18.11.2022 Date Revised 02.12.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1097/QAD.0000000000003372 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM348958439 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM348958439 | ||
003 | DE-627 | ||
005 | 20231226041522.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/QAD.0000000000003372 |2 doi | |
028 | 5 | 2 | |a pubmed24n1163.xml |
035 | |a (DE-627)NLM348958439 | ||
035 | |a (NLM)36382436 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Del Amo, Julia |e verfasserin |4 aut | |
245 | 1 | 0 | |a Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.11.2022 | ||
500 | |a Date Revised 02.12.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. | ||
520 | |a BACKGROUND: Effective, safe, and affordable antivirals are needed for coronavirus disease 2019 (COVID-19). Several lines of research suggest that tenofovir may be effective against COVID-19, but no large-scale human studies with appropriate adjustment for comorbidities have been conducted | ||
520 | |a METHODS: We studied HIV-positive individuals on antiretroviral therapy (ART) in 2020 at 69 HIV clinics in Spain. We collected data on sociodemographics, ART, CD4+ cell count, HIV-RNA viral-load, comorbidities and the following outcomes: laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, COVID-19 hospitalization, intensive care unit (ICU) admission and death. We compared the 48-week risks for individuals receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamide (TAF)/FTC, abacavir (ABC)/lamivudine (3TC), and other regimes. All estimates were adjusted for clinical and sociodemographic characteristics via inverse probability weighting | ||
520 | |a RESULTS: Of 51 558 eligible individuals, 39.6% were on TAF/FTC, 11.9% on TDF/FTC, 26.6% on ABC/3TC, 21.8% on other regimes. There were 2402 documented SARS-CoV-2 infections (425 hospitalizations, 45 ICU admissions, 37 deaths). Compared with TAF/FTC, the estimated risk ratios (RR) (95% confidence interval) of hospitalization were 0.66 (0.43, 0.91) for TDF/FTC and 1.29 (1.02, 1.58) for ABC/3TC, the RRs of ICU admission were 0.28 (0.11, 0.90) for TDF/FTC and 1.39 (0.70, 2.80) for ABC/3TC, and the RRs of death were 0.37 (0.23, 1.90) for TDF/FTC and 2.02 (0.88-6.12) for ABC/3TC. The corresponding RRs of hospitalization for TDF/FTC were 0.49 (0.24, 0.81) in individuals ≥50 years and 1.15 (0.59, 1.93) in younger individuals | ||
520 | |a DISCUSSION: Compared with other antiretrovirals, TDF/FTC lowers COVID-19 severity among HIV-positive individuals with virological control. This protective effect may be restricted to individuals aged 50 years and older | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 7 | |a Emtricitabine |2 NLM | |
650 | 7 | |a G70B4ETF4S |2 NLM | |
650 | 7 | |a Lamivudine |2 NLM | |
650 | 7 | |a 2T8Q726O95 |2 NLM | |
650 | 7 | |a Tenofovir |2 NLM | |
650 | 7 | |a 99YXE507IL |2 NLM | |
650 | 7 | |a Anti-HIV Agents |2 NLM | |
650 | 7 | |a Drug Combinations |2 NLM | |
700 | 1 | |a Polo, Rosa |e verfasserin |4 aut | |
700 | 1 | |a Moreno, Santiago |e verfasserin |4 aut | |
700 | 1 | |a Martínez, Esteban |e verfasserin |4 aut | |
700 | 1 | |a Cabello, Alfonso |e verfasserin |4 aut | |
700 | 1 | |a Iribarren, José Antonio |e verfasserin |4 aut | |
700 | 1 | |a Curran, Adria |e verfasserin |4 aut | |
700 | 1 | |a Macías, Juan |e verfasserin |4 aut | |
700 | 1 | |a Montero, Marta |e verfasserin |4 aut | |
700 | 1 | |a Dueñas, Carlos |e verfasserin |4 aut | |
700 | 1 | |a Mariño, Ana I |e verfasserin |4 aut | |
700 | 1 | |a de la Cámara, Santiago Pérez |e verfasserin |4 aut | |
700 | 1 | |a Díaz, Asuncion |e verfasserin |4 aut | |
700 | 1 | |a Arribas, José Ramón |e verfasserin |4 aut | |
700 | 1 | |a Jarrín, Inma |e verfasserin |4 aut | |
700 | 1 | |a Hernán, Miguel A |e verfasserin |4 aut | |
700 | 0 | |a on behalf of the CoVIHd Collaboration in Spain |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t AIDS (London, England) |d 1988 |g 36(2022), 15 vom: 01. Dez., Seite 2171-2179 |w (DE-627)NLM012619280 |x 1473-5571 |7 nnns |
773 | 1 | 8 | |g volume:36 |g year:2022 |g number:15 |g day:01 |g month:12 |g pages:2171-2179 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/QAD.0000000000003372 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 36 |j 2022 |e 15 |b 01 |c 12 |h 2171-2179 |